FindTrial
Sign In

The effect of methotrexate or tripterygium on polymyalgia rheumaica

The effect of methotrexate or tripterygium on PMR

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019715
Enrollment
Unknown
Registered
2018-11-24
Start date
2018-12-01
Completion date
Unknown
Last updated
2018-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polymyalgia rheumaica

Interventions

1:GC
2:GC+MTX
3:GC + Trip

Sponsors

Affiliated Hospital of Wannan Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. aged from 50 to 85 years old; 2. meet the 2016 ACR and/or EULAR PMR classification criterion; 3. Primary PMR patients without treated with glucocorticoid; 4. VAS >50; 5. CRP > 2 fold UNL.

Exclusion criteria

Exclusion criteria: 1. Clinical or pathological indicates the patients got GCA; 2. Combined with severe liver and kidney dysfunction; 3. With a history of malignant tumor for nearly 3 years; 4. Allergic to triptolide.

Design outcomes

Primary

MeasureTime frame
Disease acitivity;—

Secondary

MeasureTime frame
ESR;Stiffness time;—

Countries

China

Contacts

Public ContactLiang Xv

Affiliated Hospital of Wannan Medical College

zhangruijunyc@126.com+86 18315348418

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026